Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.42 |
| ▸ | LCK | P06239 | 3/20 | 0.42 |
| ▸ | HCK | P08631 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | TEK | Q02763 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13051737 | 0.88 | AURKA (0.47) | KMT2AMEN1AURKASMN1; SMN2MAPT | |
| SCHEMBL10096607 | 0.87 | GAA (0.40) | KDRLCKHCKSRCABL1 | |
| SCHEMBL13051738 | 0.85 | ABL1 (0.44) | KDRLCKHCKSRCABL1 | |
| SCHEMBL10252550 | 0.83 | HRH2 (0.42) | AURKA | |
| SCHEMBL10251064 | 0.81 | MTNR1B (0.48) | KDRKMT2AMEN1TP53HPGD | |
| SCHEMBL13151789 | 0.81 | ALDH1A1 (0.47) | GAAKMT2AMEN1SMN1; SMN2TP53 | |
| SCHEMBL10252492 | 0.79 | KCNQ2 (0.41) | LCKSRCRETKITGAA | |
| SCHEMBL13152369 | 0.79 | RAB9A (0.47) | GAANPSR1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL13151929 | 0.79 | KCNQ2 (0.43) | NPSR1KMT2AMEN1SMN1; SMN2TP53 | |
| SCHEMBL13152745 | 0.79 | HPGD (0.41) | KDRNPSR1KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010118009-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | KDR 4728/4885LCK 1910/4885HCK 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.